282 related articles for article (PubMed ID: 15782098)
1. 5-fluorouracil intra-arterial infusion combined with systemic gemcitabine for unresectable pancreatic cancer.
Takamori H; Kanemitsu K; Tsuji T; Tanaka H; Chikamoto A; Nakahara O; Hiraoka T; Ikeda O; Kudo K; Imuta M; Yamashita Y
Pancreas; 2005 Apr; 30(3):223-6. PubMed ID: 15782098
[TBL] [Abstract][Full Text] [Related]
2. Intra-arterial continuous infusion for treatment of pancreatic and biliary tract cancer.
Zanon C; Alabiso O; Grosso M; Buosi R; Chiappino I; Clara R; Satolli A; Zai S; Bortolini M; Botta M; Mussa A
Int J Pancreatol; 2000 Jun; 27(3):225-33. PubMed ID: 10952405
[TBL] [Abstract][Full Text] [Related]
3. Unresectable pancreatic cancer: arterial embolization to achieve a single blood supply for intraarterial infusion of 5-fluorouracil and full-dose IV gemcitabine.
Tanaka T; Sho M; Nishiofuku H; Sakaguchi H; Inaba Y; Nakajima Y; Kichikawa K
AJR Am J Roentgenol; 2012 Jun; 198(6):1445-52. PubMed ID: 22623561
[TBL] [Abstract][Full Text] [Related]
4. A Phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable advanced pancreatic cancer after vascular supply distribution via superselective embolization.
Miyanishi K; Ishiwatari H; Hayashi T; Takahashi M; Kawano Y; Takada K; Ihara H; Okuda T; Takanashi K; Takahashi S; Sato Y; Matsunaga T; Homma H; Kato J; Niitsu Y
Jpn J Clin Oncol; 2008 Apr; 38(4):268-74. PubMed ID: 18375446
[TBL] [Abstract][Full Text] [Related]
5. Randomised trial of gemcitabine versus flec regimen given intra-arterially for patients with unresectable pancreatic cancer.
Cantore M; Fiorentini G; Luppi G; Rosati G; Caudana R; Piazza E; Comella G; Ceravolo C; Miserocchi L; Mambrini A; Del Freo A; Zamagni D; Aitini E; Marangolo M
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):51-7. PubMed ID: 16767907
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine and protracted 5-FU for advanced pancreatic cancer. A phase II study.
Kurtz JE; Kohser F; Négrier S; Trillet-Lenoir V; Walter S; Limacher JM; Untereiner M; Kayitalire L; Jaeck D; Dufour P
Hepatogastroenterology; 2000; 47(35):1450-3. PubMed ID: 11100374
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology.
Cantore M; Fiorentini G; Luppi G; Rosati G; Caudana R; Piazza E; Comella G; Ceravolo C; Miserocchi L; Mambrini A; Del Freo A; Zamagni D; Rabbi C; Marangolo M
J Chemother; 2004 Dec; 16(6):589-94. PubMed ID: 15700852
[TBL] [Abstract][Full Text] [Related]
8. Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer.
Rauch DP; Maurer CA; Aebi S; Pampallona S; Friess H; Ludwig CU; Büchler MW; Borner MM
Oncology; 2001; 60(1):43-8. PubMed ID: 11150907
[TBL] [Abstract][Full Text] [Related]
9. Continuous transarterial infusion chemotherapy with gemcitabine and 5-Fluorouracil for advanced pancreatic carcinoma.
Hong GB; Zhou JX; Sun HB; Li CY; Song LQ
Asian Pac J Cancer Prev; 2012; 13(6):2669-73. PubMed ID: 22938439
[TBL] [Abstract][Full Text] [Related]
10. [A case of postoperative multiple liver metastases of pancreatic cancer successfully treated by combination chemotherapy with weekly high-dose 5-FU hepatic arterial infusion plus systemic infusion of gemcitabine].
Doh J; Sho M; Tanaka T; Yamada T; Nomi T; Akahori T; Yamato I; Nishiofuku H; Tamamoto T; Hasegawa M; Kichikawa K; Nakajima Y
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2087-9. PubMed ID: 20037332
[TBL] [Abstract][Full Text] [Related]
11. Weekly gemcitabine and 24-hour infusional 5-fluorouracil in advanced pancreatic cancer: a phase I-II study.
Barone C; Cassano A; Corsi DC; Pozzo C; Longo R; Schinzari G; Quirino M; Battelli C; Basso M
Oncology; 2003; 64(2):139-45. PubMed ID: 12566911
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
[TBL] [Abstract][Full Text] [Related]
13. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
14. Duodenal ischemia and upper GI bleeding are dose-limiting toxicities of 24-h continuous intra-arterial pancreatic perfusion of gemcitabine following vascular isolation of the pancreatic head: early results from the Regional Chemotherapy in Locally Advanced Pancreatic Cancer (RECLAP) study.
Beane JD; Griffin KF; Levy EB; Pandalai P; Wood B; Abi-Jaoudeh N; Beresnev T; Shutack Y; Webb CC; Avital I; Rudloff U
Invest New Drugs; 2015 Feb; 33(1):109-18. PubMed ID: 25236592
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer.
El-Rayes BF; Zalupski MM; Shields AF; Vaishampayan U; Heilbrun LK; Jain V; Adsay V; Day J; Philip PA
J Clin Oncol; 2003 Aug; 21(15):2920-5. PubMed ID: 12885810
[TBL] [Abstract][Full Text] [Related]
16. Intra-arterial infusion chemotherapy with 5-fluorouracil and cisplatin in advanced pancreatic cancer: a feasibility study.
Sasada T; Denno R; Tanaka T; Kanai M; Mizukami Y; Kohno S; Takabayashi A
Am J Clin Oncol; 2008 Feb; 31(1):71-8. PubMed ID: 18376231
[TBL] [Abstract][Full Text] [Related]
17. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.
Reni M; Cereda S; Mazza E; Passoni P; Nicoletti R; Balzano G; Zerbi A; Arcidiacono PG; Staudacher C; Di Carlo V
Am J Clin Oncol; 2008 Apr; 31(2):145-50. PubMed ID: 18391598
[TBL] [Abstract][Full Text] [Related]
18. Palliative first-line treatment with weekly high-dose 5-fluorouracil as 24h-infusion and gemcitabine in metastatic pancreatic cancer (UICC IV).
Roehrig S; Wein A; Albrecht H; Konturek PC; Reulbach U; Männlein G; Wolff K; Ostermeier N; Hohenberger W; Hahn EG; Boxberger F
Med Sci Monit; 2010 Mar; 16(3):CR124-131. PubMed ID: 20190682
[TBL] [Abstract][Full Text] [Related]
19. A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
Davis EJ; Griffith KA; Kim EJ; Ruch JM; McDonnell KJ; Zalupski MM
Am J Clin Oncol; 2018 Feb; 41(2):128-132. PubMed ID: 26535993
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer.
Lee J; Park JO; Kim WS; Lee SI; Song SY; Lim DH; Choi SH; Heo JS; Lee KT; Lee JK; Kim K; Jung CW; Im YH; Lee MH; Kang WK; Park K
Oncology; 2004; 66(1):32-7. PubMed ID: 15031596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
